Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Current Opinion in Pulmonary Medicine|February 4, 2006
Chronic obstructive pulmonary disease: effects beyond the lungsVijay P Balasubramanian, Basil VarkeyWMJ : Official Publication of the State Medical Society of Wisconsin|May 9, 2006
Pneumocystis carinii pneumonia with pleural effusion in a non-HIV hostVijay P Balasubramanian, Richard A Komorowski, Linus H Santo TomasPulmonary Circulation|March 28, 2018
Dosing characteristics of oral treprostinil in real-world clinical practiceVijay P Balasubramanian, Chad R Messick, Meredith Broderick, et al.Pulmonary Circulation|May 26, 2021
Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver surveyParesh C Giri, Gizelle J Stevens, Jeanette Merrill-Henry, et al.Pulmonary Circulation|May 4, 2022
Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient settingVijay P Balasubramanian, Zeenat Safdar, Margaret R Sketch, et al.Pulmonary Pharmacology & Therapeutics|December 1, 2020
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinilFranck F Rahaghi, Roblee P Allen, Vijay P Balasubramanian, et al.Pulmonary Circulation|July 7, 2017
Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulationFranck F Rahaghi, Jeremy P Feldman, Roblee P Allen, et al.Pulmonary Circulation|July 4, 2017
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus documentFranck F Rahaghi, Hassan M Alnuaimat, Rana L A Awdish, et al.Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.Pageof 1